国家卫健委：“十四五”期间我国卫生健康科技整体实力持续提升

Core Insights - The "14th Five-Year Plan" period has seen significant advancements in health technology innovation in China, with a focus on new drug and vaccine development, medical device innovation, and high-level disease prevention and treatment solutions [1][2][3] Group 1: New Drug and Vaccine Development - China's share of new drugs in global research exceeds 20%, ranking second globally, with several innovative domestic drugs like Sugli monoclonal antibody and Enzalutamide receiving approval [1] - The domestically developed HPV vaccine has improved accessibility and affordability, with the nine-valent HPV vaccine recently launched for broader immunization options for women [1] Group 2: Medical Device Innovation - The domestically developed photon counting CT has improved spatial resolution by 2-3 times compared to traditional CT, with faster scanning speeds and significantly reduced radiation doses [2] - Successful development of orthopedic surgical robots and endoscopic soft tissue surgical robots has enhanced surgical precision and reduced patient trauma [2] - High-end medical equipment such as ECMO, artificial hearts, and proton heavy ion therapy devices have been independently developed and are now in clinical use, improving patient access and outcomes [2] Group 3: High-Level Disease Prevention and Treatment Solutions - Research supported by national technology initiatives has increased the treatment efficacy for difficult-to-treat metastatic colorectal cancer from 13% to 44%, with a 61% extension in progression-free survival [3] - The average time for patients to receive thrombolytic therapy for acute stroke has been reduced from 60 minutes to under 30 minutes, significantly enhancing treatment effectiveness [3] - Development of a diagnostic and treatment system for systemic lupus erythematosus has achieved precise prediction and assessment of disease progression, establishing a personalized treatment model that is internationally leading [3]